BIGUANIDES
Oral medications

Metformin
Glucophage®
500 mg - 850 mg
OD to TID
Maximum daily dose: 2550 mg
Covered
- Characteristics and clinical considerations

Metformin ER
Glumetza®
500 mg - 1000 mg
OD
Maximum daily dose: 2000 mg
Not covered / Private coverage
- Characteristics and clinical considerations

ALPHA-GLUCOSIDASE INHIBITOR
Oral medications

Acarbose
GlucobayTM
50 mg - 100 mg
OD to TID
Maximum daily dose: 300 mg
Covered
How to initiate
- Characteristics and clinical considerations

DPP-4 INHIBITORS
Oral medications

Alogliptin
Nesina®
6.25 mg - 12.5 mg - 25 mg
OD
Code EN148-149-167
- Characteristics and clinical considerations

Alogliptin and Metformin
KazanoTM
12.5 mg/500 mg - 12.5 mg/850 mg - 12.5 mg/1000 mg
BID
Code EN150
- Characteristics and clinical considerations

Linagliptin
Trajenta®
5 mg
OD
Code EN148-167
- Characteristics and clinical considerations

Linagliptin and Metformin
JentaduetoTM
2.5 mg/500 mg - 2.5 mg/850 mg - 2.5 mg/1000 mg
BID
Code EN150
- Characteristics and clinical considerations

Saxagliptin
Onglyza®
2.5 mg - 5 mg
OD
Code EN148-149
- Characteristics and clinical considerations

Saxagliptin and Metformin
Komboglyze®
2.5 mg/500 mg - 2.5 mg/850 mg - 2.5 mg/1000 mg
BID
Code EN150
- Characteristics and clinical considerations

Sitagliptin
Januvia®
25 mg - 50 mg - 100 mg
OD
Code EN148-167
- Characteristics and clinical considerations

Sitagliptin and Metformin
Janumet®
50 mg/500 mg - 50 mg/850 mg - 50 mg/1000 mg
BID
Code EN150
- Characteristics and clinical considerations

Sitagliptin and Metformin ER
Janumet® XR
50 mg/500 mg - 50 mg/1000 mg - 100 mg/1000 mg
OD
Code EN150
- Characteristics and clinical considerations

SGLT2 INHIBITORS
Oral medications

Canaglifozin
Invokana®
100 mg - 300 mg
OD
Code EN148-149-167
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Canaglifozin and Metformin
Invokamet®
50 mg/500 mg - 50 mg/1000 mg - 150 mg/500 mg - 150 mg/1000 mg
BID
Not covered / Private coverage
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Dapagliflozin and Metformin
Xigduo®
5 mg/850 mg - 5 mg/1000 mg
BID
Code EN150
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Empagliflozin and Linagliptin
Glyxambi®
10 mg/ 5 mg - 25 mg/5 mg
OD
Not covered / Private coverage
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Empagliflozine and Metformin
SynjardyTM
5 mg/500 mg - 5/850 mg - 5 mg/1000 mg - 12.5 mg/500 mg - 12.5 mg/850 mg - 12.5 mg/1000 mg
BID
Code EN219
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

INSULIN SECRETAGOGUES
Oral medications

Gliclazide
Diamicron®
80 mg
OD to BID
Maximum daily dose: 320 mg
Covered
- Characteristics and clinical considerations

Gliclazide Modified Release
Diamicron®MR
30 mg - 60 mg
OD
Maximum daily dose: 120 mg
Covered
- Characteristics and clinical considerations

Glimepiride
Amaryl®
1 mg - 2 mg - 4 mg
OD to BID
Maximum daily dose: 8 mg
Code EN23
- Characteristics and clinical considerations

Glyburide
Diabeta®
2.5 mg - 5 mg
OD to BID
Maximum daily dose: 20 mg
Covered
- Characteristics and clinical considerations

Repaglinide
GlucoNorm®
0.5 mg - 1 mg - 2 mg
OD to TID AC
Maximum daily dose: 16 mg
Covered
- Characteristics and clinical considerations

THIAZOLIDINEDIONES (TZD)
Oral medications

Pioglitazone
Actos®
15 mg - 30 mg - 45 mg
OD
Code EN117-118-119-121
- Characteristics and clinical considerations

Rosiglitazone
Avandia®
2 mg - 4 mg - 8 mg
OD
Code EN117-118-119-121
- Characteristics and clinical considerations

GLP-1R AGONISTS
Injectable medications s/c

Dulaglutide
Trulicity®
0.75 mg - 1.5 mg
Once-Weekly
Stability at room temperature : 14 days
Private coverage or RAMQ form
(Infolettre RAMQ)
Instructions for Use - Video
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Liraglutide
Victoza®
0.6 mg - 1.2 mg - 1.8 mg
OD
Stability at room temperature : 30 days
Private coverage or RAMQ form
(Infolettre RAMQ)
Video demo. of the injection technic
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Lixisenatide
AdlyxineTM
10 ug/dose (0.05 mg/ml)
20 ug/dose (0.1 mg/ml)
OD
Stability at room temperature : 14 days
Not covered / Private coverage
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Glargine U100 (100 units/ml) / Lixisenatide (33 mcg/ml)
SoliquaTM
Maximum recommended daily dose is 60 units:
Glargine U100 60 units / Lixisenatide 20 mcg
Not Covered / Private coverage
How to Inject (video)
How to Inject (pdf)
Therapy Initiation and Titration
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Degludec (100 units/ml) / Liraglutide (3.6 mg/ml)
Xultophy®
Maximum recommended daily dose is 50 units:
Degludec 50 units / Liraglutide 1.8 mg
Not Covered / Private coverage
Therapy Initiation and Titration
- Cardio-renal protection clinical data
- Characteristics and clinical considerations